Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inositol-requiring enzyme 1 alpha (IRE1α), encoded by the ERN1 gene, is a type I transmembrane protein and the most evolutionarily conserved sensor of the unfolded protein response (UPR) in the endoplasmic reticulum (ER) [1, 10]. It possesses a luminal domain that detects misfolded proteins and a cytosolic region containing both a serine/threonine kinase domain and an endoribonuclease (RNase) domain [1, 4]. Upon activation by ER stress, IRE1α undergoes dimerization and trans-autophosphorylation, which induces a conformational change that activates its RNase domain [7, 10]. This domain is responsible for the non-conventional splicing of XBP1 mRNA into its active form (XBP1s) and the degradation of various ER-localized mRNAs through a process called Regulated IRE1-Dependent Decay (RIDD) [1, 15]. These pathways collectively regulate cell survival, protein folding capacity, and apoptosis, making the IRE1α RNase domain a high-priority therapeutic target in cancers (such as multiple myeloma and triple-negative breast cancer), neurodegenerative diseases, and metabolic disorders [3, 4, 12]. Pharmacological modulation involves direct RNase inhibitors that bind the catalytic site (e.g., 4μ8C, STF-083010) and allosteric kinase inhibitors (KIRAs) that prevent RNase activation [1, 6, 14].
Direct inhibition of the RNase catalytic site or allosteric inhibition via the kinase domain to prevent RNase activation and subsequent XBP1 splicing and RIDD activity.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inositol-requiring enzyme 1 alpha (IRE1α) (IRE1α).